SWTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.61%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $25,242,355.68

SpringWorks Therapeutics Insider Trading History Chart

SpringWorks Therapeutics Share Price & Price History

^$47.41

▼ -0.08 (-0.17%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

SpringWorks Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2025	Badreddin Edris	COO	Sell	20,000	$54.23	$1,084,600.00	169,712
3/3/2025	Saqib Islam	CEO	Sell	49,000	$54.24	$2,657,760.00	954,869
2/20/2025	Bhavesh Ashar	Insider	Sell	1,016	$61.19	$62,169.04	62,053
2/20/2025	Daniel Lynch	Director	Sell	47,600	$60.22	$2,866,472.00	82,944
2/20/2025	Saqib Islam	CEO	Sell	29,328	$60.30	$1,768,478.40	1,034,625
2/14/2025	Daniel Lynch	Director	Sell	400	$60.00	$24,000.00	130,544
2/14/2025	Saqib Islam	CEO	Sell	10,672	$59.92	$639,466.24	1,063,953
2/10/2025	Badreddin Edris	COO	Sell	30,000	$53.13	$1,593,900.00	189,712
2/10/2025	Daniel Lynch	Director	Sell	175,000	$54.46	$9,530,500.00	130,944
2/10/2025	Daniel Pichl	Insider	Sell	29,750	$54.36	$1,617,210.00	50,762
2/10/2025	Saqib Islam	CEO	Sell	48,000	$53.30	$2,558,400.00	1,002,502
12/3/2024	Badreddin Edris	COO	Sell	20,000	$41.97	$839,400.00	209,600
2/16/2024	Daniel Pichl	Insider	Sell	15,000	$50.10	$751,500.00	45,212
7/19/2023	Julie Hambleton	Director	Sell	2,418	$29.31	$70,871.58	4,648
6/20/2023	Julie Hambleton	Director	Sell	2,400	$26.92	$64,608.00	7,066
3/15/2023	Julie Hambleton	Director	Sell	1,106	$31.50	$34,839.00	4,818
1/26/2023	Daniel Pichl	Insider	Sell	858	$31.00	$26,598.00	35,203
9/12/2022	Orbimed Advisors Llc	Major Shareholder	Sell	153,897	$31.96	$4,918,548.12	5,599,842

See Full Table

SEC Filings (Institutional Ownership Changes) for SpringWorks Therapeutics (NASDAQ:SWTX)

Institutional Buying and Selling by Quarter

SpringWorks Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	31,181	$1.13M	0.0%	-10.9%	0.042%
3/18/2025	California State Teachers Retirement System	56,220	$2.03M	0.0%	+5.0%	0.075%
2/19/2025	GF Fund Management CO. LTD.	1,562	$56K	0.0%	N/A	0.002%
2/18/2025	Palisades Investment Partners LLC	134,445	$4.86M	2.0%	+9.9%	0.181%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	119,052	$4.30M	0.0%	+19.4%	0.160%
2/17/2025	Woodline Partners LP	1,490,136	$53.84M	0.4%	+7.9%	2.003%
2/17/2025	Zimmer Partners LP	142,300	$5.14M	0.1%	N/A	0.191%
2/17/2025	Velan Capital Investment Management LP	185,520	$6.70M	5.8%	N/A	0.249%
2/17/2025	Squarepoint Ops LLC	11,864	$0.43M	0.0%	-59.2%	0.016%
2/17/2025	State of Wyoming	1,530	$55K	0.0%	+39.5%	0.002%
2/17/2025	Tema Etfs LLC	30,811	$1.11M	0.5%	N/A	0.041%
2/17/2025	Sphera Funds Management LTD.	100,000	$3.61M	0.7%	N/A	0.134%
2/17/2025	Rafferty Asset Management LLC	122,943	$4.44M	0.0%	-11.0%	0.165%
2/17/2025	ProShare Advisors LLC	22,883	$0.83M	0.0%	+31.7%	0.031%
2/17/2025	Patient Square Capital LP	93,137	$3.37M	1.3%	N/A	0.125%
2/17/2025	Main Management ETF Advisors LLC	21,360	$0.77M	0.0%	-8.2%	0.029%
2/17/2025	Nuveen Asset Management LLC	183,761	$6.64M	0.0%	-38.3%	0.247%
2/17/2025	Orbimed Advisors LLC	1,255,031	$45.34M	1.0%	-9.8%	1.687%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	44,013	$1.59M	0.0%	+2.2%	0.059%
2/17/2025	Integral Health Asset Management LLC	100,000	$3.61M	0.3%	N/A	0.134%
2/17/2025	J. Goldman & Co LP	53,503	$1.93M	0.1%	-15.4%	0.072%
2/17/2025	Ensign Peak Advisors Inc	19,041	$0.69M	0.0%	-88.5%	0.026%
2/17/2025	Deutsche Bank AG	60,714	$2.19M	0.0%	+47.5%	0.082%
2/17/2025	D. E. Shaw & Co. Inc.	387,733	$14.01M	0.0%	-46.5%	0.521%
2/17/2025	Deep Track Capital LP	3,460,756	$125.04M	4.7%	-10.0%	4.652%
2/17/2025	Duquesne Family Office LLC	859,694	$31.06M	0.8%	+21.9%	1.156%
2/17/2025	Brevan Howard Capital Management LP	8,494	$0.31M	0.0%	-3.0%	0.011%
2/17/2025	Balyasny Asset Management L.P.	85,761	$3.10M	0.0%	N/A	0.115%
2/17/2025	Bank of America Corp DE	416,888	$15.06M	0.0%	-51.6%	0.560%
2/17/2025	BNP Paribas Financial Markets	9,719	$0.35M	0.0%	N/A	0.013%
2/17/2025	Ameriprise Financial Inc.	971,099	$35.09M	0.0%	+21.7%	1.305%
2/17/2025	Algert Global LLC	35,340	$1.28M	0.0%	N/A	0.048%
2/17/2025	ArrowMark Colorado Holdings LLC	1,499,134	$54.16M	0.7%	+0.5%	2.015%
2/17/2025	Ally Bridge Group NY LLC	54,692	$1.98M	1.7%	-76.0%	0.074%
2/14/2025	Boxer Capital Management LLC	3,421,541	$123.62M	10.4%	N/A	4.599%
2/14/2025	Soros Fund Management LLC	600,470	$21.70M	0.3%	+7.4%	0.807%
2/14/2025	Schonfeld Strategic Advisors LLC	194,043	$7.01M	0.0%	-2.6%	0.261%
2/14/2025	Northern Trust Corp	655,678	$23.69M	0.0%	+8.8%	0.881%
2/14/2025	The Manufacturers Life Insurance Company	407,683	$14.73M	0.0%	+42.8%	0.548%
2/14/2025	Quarry LP	10,000	$0.36M	0.1%	+66.7%	0.013%
2/14/2025	Boothbay Fund Management LLC	10,978	$0.40M	0.0%	-14.2%	0.015%
2/14/2025	Virtus ETF Advisers LLC	9,037	$0.33M	0.1%	+7.4%	0.012%
2/14/2025	Nebula Research & Development LLC	25,020	$0.90M	0.1%	-21.9%	0.034%
2/14/2025	Lord Abbett & CO. LLC	945,808	$34.17M	0.1%	-11.6%	1.271%
2/14/2025	Voya Investment Management LLC	796,684	$28.78M	0.0%	+9.3%	1.071%
2/14/2025	Syon Capital LLC	13,556	$0.49M	0.0%	N/A	0.018%
2/14/2025	Price T Rowe Associates Inc. MD	3,274,786	$118.32M	0.0%	-6.9%	4.402%
2/14/2025	Rock Springs Capital Management LP	328,911	$11.88M	0.5%	+64.6%	0.442%
2/14/2025	Stifel Financial Corp	23,713	$0.86M	0.0%	-7.7%	0.032%
2/14/2025	Tower Research Capital LLC TRC	8,931	$0.32M	0.0%	+132.9%	0.012%
2/14/2025	MetLife Investment Management LLC	42,089	$1.52M	0.0%	+6.9%	0.057%
2/14/2025	Dimensional Fund Advisors LP	717,714	$25.93M	0.0%	-1.0%	0.965%
2/14/2025	First Trust Advisors LP	13,097	$0.47M	0.0%	+19.3%	0.018%
2/14/2025	Capital International Investors	2,361,746	$85.33M	0.0%	+92.7%	3.175%
2/13/2025	Guggenheim Capital LLC	20,129	$0.73M	0.0%	-19.4%	0.027%
2/13/2025	Barclays PLC	156,123	$5.64M	0.0%	+0.3%	0.210%
2/13/2025	Kennedy Capital Management LLC	78,352	$2.83M	0.1%	+4.9%	0.105%
2/13/2025	Legal & General Group Plc	65,765	$2.38M	0.0%	+1.7%	0.088%
2/13/2025	Invesco Ltd.	557,067	$20.13M	0.0%	+6.2%	0.749%
2/13/2025	FMR LLC	11,157,960	$403.14M	0.0%	+0.2%	14.999%
2/13/2025	Finepoint Capital LP	748,752	$27.05M	1.7%	+15.0%	1.007%
2/13/2025	Russell Investments Group Ltd.	112,942	$4.08M	0.0%	-19.4%	0.152%
2/13/2025	Envestnet Asset Management Inc.	121,763	$4.40M	0.0%	+1.3%	0.164%
2/13/2025	Wells Fargo & Company MN	158,014	$5.71M	0.0%	+6.6%	0.212%
2/12/2025	Huntington National Bank	694	$25K	0.0%	+38.2%	0.001%
2/12/2025	Massachusetts Financial Services Co. MA	592,645	$21.41M	0.0%	-7.9%	0.797%
2/12/2025	Headlands Technologies LLC	4,746	$0.17M	0.0%	N/A	0.006%
2/12/2025	Alliancebernstein L.P.	76,431	$2.76M	0.0%	-49.3%	0.103%
2/12/2025	Wellington Management Group LLP	31,181	$1.13M	0.0%	-10.9%	0.042%
2/12/2025	Schroder Investment Management Group	168,209	$6.11M	0.0%	+93.6%	0.226%
2/12/2025	DnB Asset Management AS	11,875	$0.43M	0.0%	-4.3%	0.016%
2/12/2025	Orion Portfolio Solutions LLC	32,997	$1.19M	0.0%	+10.2%	0.044%
2/12/2025	Pictet Asset Management Holding SA	2,391,412	$86.40M	0.1%	+24.2%	3.215%
2/12/2025	Norges Bank	186,503	$6.74M	0.0%	N/A	0.251%
2/12/2025	NEOS Investment Management LLC	30,811	$1.11M	0.0%	+51.2%	0.041%
2/12/2025	BIT Capital GmbH	53,539	$1.93M	0.2%	+18.7%	0.072%
2/12/2025	JPMorgan Chase & Co.	227,935	$8.24M	0.0%	-10.6%	0.306%
2/11/2025	Segall Bryant & Hamill LLC	193,459	$6.99M	0.1%	+43.4%	0.260%
2/11/2025	Corebridge Financial Inc.	34,178	$1.24M	0.0%	-7.0%	0.046%
2/11/2025	Vanguard Group Inc.	7,158,871	$258.65M	0.0%	+6.6%	9.623%
2/11/2025	KLP Kapitalforvaltning AS	12,600	$0.46M	0.0%	N/A	0.017%
2/11/2025	Sei Investments Co.	28,309	$1.02M	0.0%	-9.2%	0.038%
2/11/2025	Teacher Retirement System of Texas	17,609	$0.64M	0.0%	+26.4%	0.024%
2/11/2025	Platinum Investment Management Ltd.	46,895	$1.69M	0.1%	N/A	0.063%
2/10/2025	Cibc World Markets Corp	6,433	$0.23M	0.0%	N/A	0.009%
2/10/2025	Swiss National Bank	116,800	$4.22M	0.0%	+7.4%	0.157%
2/7/2025	AlphaQuest LLC	1,004	$36K	0.0%	+70.2%	0.001%
2/7/2025	PNC Financial Services Group Inc.	5,712	$0.21M	0.0%	-10.4%	0.008%
2/7/2025	Candriam S.C.A.	164,015	$5.93M	0.0%	-80.6%	0.220%
2/6/2025	Raymond James Financial Inc.	291,356	$10.53M	0.0%	N/A	0.392%
2/6/2025	Arizona State Retirement System	17,206	$0.62M	0.0%	+7.5%	0.023%
2/6/2025	M&T Bank Corp	20,155	$0.73M	0.0%	+16.0%	0.027%
2/6/2025	Assetmark Inc.	48,216	$1.74M	0.0%	+4.8%	0.065%
2/6/2025	Victory Capital Management Inc.	614,923	$22.22M	0.0%	-2.3%	0.827%
2/6/2025	Charles Schwab Investment Management Inc.	605,248	$21.87M	0.0%	+0.5%	0.814%
2/5/2025	US Bancorp DE	4,336	$0.16M	0.0%	+56.0%	0.006%
2/5/2025	Mutual of America Capital Management LLC	116,932	$4.23M	0.0%	+1.6%	0.157%
2/5/2025	Oppenheimer Asset Management Inc.	12,559	$0.45M	0.0%	-6.2%	0.017%
2/4/2025	Los Angeles Capital Management LLC	61,760	$2.23M	0.0%	+30.8%	0.083%
2/4/2025	Bank of New York Mellon Corp	195,942	$7.08M	0.0%	-13.7%	0.263%

Data available starting January 2016

See Full Table

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $47.41

$46.00

$47.88

50 Day Range

MA: $47.98

$34.63

$59.93

52 Week Range

Now: $47.41

$28.21

$62.00

Volume

1,332,631 shs

Average Volume

1,297,676 shs

Market Capitalization

$3.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Who are the company insiders with the largest holdings of SpringWorks Therapeutics?: SpringWorks Therapeutics' top insider investors include:
Saqib Islam (CEO)
Badreddin Edris (COO)
Daniel Lynch (Director)
Bhavesh Ashar (Insider)
Daniel Pichl (Insider)
Julie Hambleton (Director)
Learn More about top insider investors at SpringWorks Therapeutics.
Who are the major institutional investors of SpringWorks Therapeutics?: SpringWorks Therapeutics' top institutional shareholders include:
FMR LLC — 15.00%
Vanguard Group Inc. — 9.62%
Deep Track Capital LP — 4.65%
Boxer Capital Management LLC — 4.60%
Price T Rowe Associates Inc. MD — 4.40%
Pictet Asset Management Holding SA — 3.21%
Learn More about top institutional investors of SpringWorks Therapeutics stock.
Which major investors are selling SpringWorks Therapeutics stock?: During the previous quarter, SWTX stock was sold by these institutional investors:
Candriam S.C.A.
Bank of America Corp DE
Deep Track Capital LP
D. E. Shaw & Co. Inc.
Price T Rowe Associates Inc. MD
Ally Bridge Group NY LLC
Ensign Peak Advisors Inc
Orbimed Advisors LLC
Within the last year, company insiders that have sold SpringWorks Therapeutics company stock include:
Saqib Islam (CEO)
Badreddin Edris (COO)
Daniel Lynch (Director)
Bhavesh Ashar (Insider)
Daniel Pichl (Insider)
Learn More investors selling SpringWorks Therapeutics stock.
Which major investors are buying SpringWorks Therapeutics stock?: During the previous quarter, SWTX stock was purchased by institutional investors including:
Boxer Capital Management LLC
Capital International Investors
Pictet Asset Management Holding SA
Vanguard Group Inc.
Raymond James Financial Inc.
Norges Bank
Velan Capital Investment Management LP
Principal Financial Group Inc.